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Abstract
Abstract Background: In ovarian cancer, the increased rate of radical surgery
comprising upper abdominal procedures has participated to improve overall
survival (OS) in advanced stages by increasing the rate of complete
cytoreductions. However, in the context of non-resectability, it is unclear whether
radical surgery should be considered when it would lead to microscopic but visible
disease (≤1 cm). We aimed to compare the survival outcomes among patients
with incomplete cytoreduction according to the extent of surgery. Methods:
Overall, 148 patients presenting with advanced stage ovarian carcinomas were
included in this retrospective study, regardless of treatment schedule. These
patients were stratified according to the extent of surgery (standard or radical).
Complete cytoreduction at the time of debulking surgery could not be carried out in
all cases. Results: Among our study population (n = 148), 96 patients underwent
standard procedures (SPs) and 52 underwent radical surgeri...
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ABSTRACT
Background. In ovarian cancer, the increased rate of
radical surgery comprising upper abdominal procedures
has participated to improve overall survival (OS) in
advanced stages by increasing the rate of complete
cytoreductions. However, in the context of non-re-
sectability, it is unclear whether radical surgery should be
considered when it would lead to microscopic but visible
disease (B1 cm). We aimed to compare the survival out-
comes among patients with incomplete cytoreduction
according to the extent of surgery.
Methods. Overall, 148 patients presenting with advanced
stage ovarian carcinomas were included in this
retrospective study, regardless of treatment schedule.
These patients were stratified according to the extent of
surgery (standard or radical). Complete cytoreduction at
the time of debulking surgery could not be carried out in all
cases.
Results. Among our study population (n = 148), 96
patients underwent standard procedures (SPs) and 52
underwent radical surgeries (RP). Patients in the SP group
had a lower Peritoneal Index Cancer (PCI) at baseline
(12.6 vs. 14.9; p = 0.049). After PCI normalization, we
observed similar OS in the SP and RP groups (39.7 vs.
43.1 months; p = 0.737), while patients in the SP group
had a higher rate of residual disease[10 mm (p\ 10-3).
Patients in the RP group had an increased rate of relapse
(p = 0.005) but no difference in disease-free survival
compared with the SP group (22.2 for SP vs. 16.3 months;
p = 0.333). Residual disease status did not impact survival
outcomes.
Conclusions. In the context of non-resectable, advanced
stage ovarian cancer, standard surgery seems as benefi-
cial as radical surgery regarding survival outcomes and
should be considered to reduce surgery-associated
morbidity.
Electronic supplementary material The online version of this
article (doi:10.1245/s10434-015-4890-8) contains supplementary
material, which is available to authorized users.
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Due to the lack of effective screening, ovarian cancer
spreading to the peritoneum often results in an advanced
stage diagnosis [International Federation of Gynecology
and Obstetrics (FIGO) stages IIIC and IV].1 It is thus
associated with poor outcomes and is considered the
leading cause of death from gynecologic cancer in devel-
oped countries.
In patients presenting with advanced stage, the mainstay
of treatment involves a combination of cytoreductive sur-
gery and paclitaxel and platinium-based chemotherapy.2,3
Surgery can be performed either primarily or after courses
of neoadjuvant chemotherapy, depending on the extent of
the initial disease and the possibility of a complete
debulking.4 This cytoreductive surgery aims to remove the
bulk of the tumor with the ideal purpose of complete
resection as the amount of residual disease is a major
prognosis parameter.2,5,6 Hence, radical procedures
involving multiple digestive tract resections, peritoneum
stripping, and upper abdominal surgery (UAS) are some-
times required to achieve complete cytoreduction.5,7
Unfortunately, in some cases complete gross resection
cannot be achieved. Several studies have observed an
inverse correlation between the amount of residual disease
and survival.8 Nevertheless, the threshold effect is still not
well determined; some authors have defined a cutoff of
1 cm9 and others have defined a cutoff of 2 cm,10,11 while
current research tends to only distinguish complete from
incomplete surgeries.3 Extensive abdominal cytoreduction
is associated with a higher complication rate, therefore the
benefit of such a procedure should be carefully evaluated.12
This poses the question of whether radical surgery should
be prioritized over standard procedures (SPs) to minimize
postoperative tumor residues.
This study aims to assess survival outcomes in women
experiencing advanced stage ovarian cancer where com-
plete cytoreduction could not be carried out. Our main goal




This study received the agreement of the local Institu-
tional Review Board. A total of 527 patients with advanced
stage ovarian cancers (FIGO stages IIIC and IV with
pleural invasion only) treated from January 2003 to
December 2007 were included, and patients were treated in
seven French referral gynecologic oncology units. All
patients with complete cytoreductive surgery were exclu-
ded; hence, only patients who underwent incomplete
cytoreductive surgery were enrolled, independently of the
amount of residual disease and the treatment schedule.
Upfront debulking surgeries, as well as interval procedures
after neoadjuvant chemotherapy, were thus considered.
The decision in treatment schedule was defined in tumor
board review and was based on clinical assessment and
laparoscopic evaluation of disease extension, concordantly
with French and international guidelines. In each referral
center, a senior surgeon mentored all surgeries and made
the decision regarding surgical extent at the time of
debulking surgery. Therefore, surgical attitudes were
homogenous in a specific center.
Subgroup Definition
Our study population was stratified according to the
extent of surgery. Standard surgery was defined as a
procedure involving hysterectomy, bilateral salpingo-
oophorectomy, rectosigmoid resection, infragastric
omentectomy, pelvic and aortic lymphadenectomy and,
when applicable, appendectomy. Radical surgery was
defined as a procedure involving standard surgery plus a
combination of UAS, multiple digestive tract resections,
abdominal organ resections (splenectomy, partial gas-
trectomy, and others), coeliac lymph node dissection, and
total abdominal peritoneum stripping. All events, demo-
graphic characteristics, histological subtypes, Peritoneal
Cancer Index (PCI), and patterns of treatment were col-
lected retrospectively.
Residual Disease Nomenclature
The terminology proposed by Chang and Bristow was
used to define residual disease.8 Residual disease measur-
ing B10 mm in maximal diameter was defined as gross
residual-1 (GR1), and residual disease [10 mm was
defined as gross residual-bulky (GRB). Reasons for
incomplete cytoreduction were unresectable carcinomato-
sis of bowel surface, deep mesenteric infiltration, or node
and coeliac involvement.
Statistical Analysis
XLSTAT software (Addinsoft, USA) was used to
perform statistical analysis. Overall survival (OS) and
disease-free survival (DFS) were computed from the date
of initial diagnosis. The first event corresponded to death of
any cause for OS, and to relapse or death for DFS. OS and
DFS curves were achieved using Kaplan–Meier or para-
metric analysis. All statistical tests were two-sided and
differences were considered significant when p\ 0.05.
The Cox proportional model was used to compute hazard
ratios (HRs).
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RESULTS
Demographics
Of 527 patients, 152 met our inclusion criteria as they
had residual disease after undergoing cytoreductive sur-
gery. We excluded the remaining patients, 374 in whom
complete cytoreduction was achieved and 1 in whom
residual disease status was unknown. Among the 152
patients with incomplete cytoreduction, 4 were secondarily
excluded due to missing data.
Considering our study population (N = 148), 96
patients underwent a standard procedure (SP group) and 52
underwent a radical surgery (RP group) (for further details
regarding surgical procedures refer to electronic supple-
mentary Tables 1 and 2). No significant differences were
observed in patient age, FIGO stages, and patterns of
treatment between the two groups (Table 1). Mean PCI
value was higher in the RP group than in the SP group
(p = 0.049). The amount of residual disease was greater
after standard surgery: GRB rate in the SP group was 45.8
versus 17.3 % in the RP group (p\ 10-3).
Surgical Extent Does Not Impact Survival Outcomes
The median follow-up was 49 months, and median DFS
and OS was 19.9 and 41.9 months, respectively (Table 1).
Both the SP and RP groups exhibited similar OS (40.2 vs.
42.7 months, respectively; p = 0.711) (Fig. 1), and there
was a trend towards reduced DFS in the RP group (16.5 vs.
22.1 months in women in the SP group; p = 0.068).
Noteworthy, patients who underwent radical procedures
were more likely to develop a relapse (p = 0.021), with an
HR for recurrence of 1.46 (p = 0.05).
TABLE 1 Comparative statistics considering the whole population
Total (N = 148) SP group (N = 96) RP group (N = 52) p-Value
Age [mean (SD)] 61.1 (9.8) 61.2 (9.8) 60.9 (9.9) 0.853
PCI [mean (SD)] 13.5 (6.2) 12.6 (6.6)a 14.9 (5.2)b 0.049*
DFS [mean (SD)] 19.9 (14.3) 22.1 (15.5) 16.5 (11.8) 0.068
OS [mean (SD)] 41.9 (18.5) 40.2 (18.1) 42.7 (19.4) 0.711
OS after relapse [mean (SD)] – 19.2 (13.5) 27.4 (15.8) 0.125
FIGO stage 0.795
IIIC 112 (75.7) 72 (75.0) 40 (76.9)
IV 36 (24.3) 24 (25.0) 12 (23.1)
Neoadjuvant CT 0.187
Yes 86 (58.1) 52 (54.2) 34 (65.4)
No 62 (41.9) 44 (45.8) 18 (34.6)
Histological type 0.079
Serous papillary 105 (70.9) 65 (67.7) 40 (76.9)
Endometrioid 18 (12.2) 13 (13.6) 5 (9.6)
Undifferentiated 18 (12.2) 15 (15.6) 3 (5.8)
Other 7 (4.7) 3 (3.1) 4 (7.7)
Residual disease, mm \10-3*
B10 95 (64.2) 52 (54.2)a 43 (82.7)b
[10 53 (35.8) 44 (45.8) 9 (17.3)
Relapse 0.005*
No 15 (12.4) 14 (19.2)a 1 (2.1)b
Yes 106 (87.6) 59 (80.1) 47 (97.9)
Condition 0.92
Alive 46 (38.0) 28 (38.4) 18 (37.5)
Dead 75 (62.0) 45 (61.6) 30 (62.5)
Data are expressed as n (%) unless otherwise specified
SP standard procedure, RP radical procedure, SD standard deviation, PCI Peritoneal Cancer Index, DFS disease-free survival, OS overall
survival, FIGO International Federation of Gynecology and Obstetrics, CT chemotherapy
* Statistical significance
a,b A statistical significance is observed in the comparison between the groups marked with a different letter
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Subgroup Analysis
To avoid possible bias due to the significant difference
of disease extent between the two groups, we only included
patients with a PCI C10 (Table 2). We observed similar
results regarding the volume of residual disease: patients in
the SP group displayed more GRB than patients in the RP
group (60.3 vs. 16.7 %, p\ 10-4). The treatment patterns
were slightly different between the two groups, with a trend
toward more neoadjuvant chemotherapy in patients in the
RP group (62.5 vs. 46.6 %; p = 0.09).
Median OS and DFS were 42 and 19.5 months,
respectively, in the subpopulation with a PCI [10
(N = 121). Similarly to non-adjusted analysis, more
recurrences were observed in the RP group (p = 0.005),
but the corresponding HR did not reach significance
(HR 1.319; p = 0.158). No significant difference regarding
DFS between the two groups was observed despite a sub-
stantial gap of 5.9 months (22.2 months in the SP group vs.
16.3 months in the RP group; p = 0.156) (Fig. 2). Con-
versely, patients in the RP group seemed to exhibit
improved OS (43.1 vs. 39.7 months) but the difference was
still not significant (p = 0.575).
Defining a cutoff at 20 for PCI, we noticed a significant
difference between the two groups regarding treatment
schedule; the rate of upfront debulking surgery was higher
in the SP group (p = 0.04) (Table 3). Furthermore, the
increased rate of relapse observed in the RP group
(p = 0.033) was associated with a significant HR for
recurrence of 2.013 (p = 0.026). In parallel, patients in the
RP group had a decreased DFS compared with the SP
group (13.6 vs. 25.4 months, respectively; p = 0.031)
(electronic supplementary Figure 1); however, both groups
displayed similar OS (37.9 months for the RP group and
35.5 months for the SP group; p = 0.55).
Residual Disease and Treatment Schedule Do Not
Modulate Prognosis
Residual disease status did not impact survival outcomes
in the study population. HR associated with GRB was
1.146 (p = 0.41) and 1.045 (p = 0.058) for OS and DFS,
respectively. Similarly, the treatment schedule did not
modulate patients’ prognosis. HR associated with neoad-
juvant chemotherapy was 1.072 (p = 0.74) and 1.15
(p = 0.43) for OS and DFS, respectively.
(A) Disease Free Survival
(B) Overall Survival
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FIG. 1 Comparative outcomes between the standard procedure and radical surgery groups for (a) disease-free survival, and (b) overall survival
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Overall, 86 patients received neoadjuvant chemotherapy
(58.1 %). Within this subgroup, DFS and OS was 18.9 and
43.4 months, respectively. The surgical approach (standard
or radical) did not affect prognosis; no significant differ-
ences were observed in OS (37.9 months for SP vs.
49.6 months for RP; p = 0.22) and DFS (20.2 months for
SP vs. 16.5 months for RP; p = 0.25). HR associated with
radical surgery was 1.12 (p = 0.51) for DFS and 0.68
(p = 0.27) for OS. Patients who underwent radical proce-
dures did not develop more recurrences compared with the
SP subgroup (p = 0.15).
A total of 62 patients underwent upfront debulking
surgery (41.9 %). DFS and OS was 22.2 and 42.5 months,
respectively. Similar to the subgroup with neoadjuvant
chemotherapy, the extent of surgery did not impact OS
(45.1 months for SP vs. 36.9 months for RP; p = 0.23) and
DFS (24.8 months for SP vs. 17.3 months for RP;
p = 0.27). HR associated with radical surgery was 1.1
(p = 0.82) for DFS and 1.37 (p = 0.52) for OS. The RP
subgroup did not display more relapses (p = 0.07).
Finally, the comparison in survival outcomes between
the four subgroups, defined according to surgical extent
and treatment schedule, showed no significant differences
(p = 0.15 and p = 0.9 for DFS and OS, respectively).
Intercenter Comparison
In all centers, maximal surgical effort was performed to
achieve complete cytoreduction whenever applicable. In
the case of non-fully resectable disease, we observed a
great heterogeneity among centers regarding surgical
extent (electronic supplementary Table 1). Two depart-
ments prioritized aggressive surgeries (100 and 73.7 %,
respectively) and reached the lowest rates of GRB disease
TABLE 2 Comparative statistics after PCI adjustment (C10)
Total (N = 121) SP group (N = 73) RP group (N = 48) p-Value
Age [mean (SD)] 62 (9.8) 62 (10) 62(9.6) 0.93
PCI [mean (SD)] 16 (4.8) 17 (5.1) 16 (4.4) 0.43
DFS [mean (SD)] 19.5 (14.4) 22.2 (16.1) 16.3 (11.3) 0.156
OS [mean (SD)] 42.0 (19.9) 39.7 (19.7) 43.1 (19.9) 0.575
OS after relapse [mean (SD)] – 19.5 (14.8) 28.4 (16.1) 0.126
FIGO stage 0.35
IIIC 93 (76.9) 54 (74.0) 39 (81.2)
IV 28 (23.1) 19 (26.0) 9 (18.8)
Neoadjuvant CT 0.09
Yes 64 (52.9) 34 (46.6) 30 (62.5)
No 57 (47.1) 39 (53.4) 18 (37.5)
Histological type 0.79
Serous papillary 90 (74.4) 53 (72.6) 37 (77.1)
Endometrioid 15 (12.4) 10 (13.7) 5 (10.4)
Undifferentiated 9 (7.4) 6 (8.2) 3 (6.2)
Other 7 (5.8) 4 (5.5) 3 (6.3)
Residual disease, mm \10-4*
B10 69 (57.0) 29 (39.7)a 40 (83.3)b
[10 52 (43.0) 44 (60.3) 8 (16.7)
Relapse 0.005*
No 15 (12.4) 14 (19.2)a 1 (2.1)b
Yes 106 (87.6) 59 (80.1) 47 (97.9)
Condition 0.92
Alive 46 (38.0) 28 (38.4) 18 (37.5)
Dead 75 (62.0) 45 (61.6) 30 (62.5)
Data are expressed as n (%) unless otherwise specified
SP standard procedure, RP radical procedure, SD standard deviation, PCI Peritoneal Cancer Index, DFS disease-free survival, OS overall
survival, FIGO International Federation of Gynecology and Obstetrics, CT chemotherapy
* Statistical significance
a,b There is a statistical significance in the comparison between the groups marked with a different letter
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(11.8 and 10.5 %, respectively); however, there was no
significant difference in OS between the seven depart-
ments. Pooling the patients according to the type of
surgical strategy of each center (aggressive vs. less
aggressive) led to similar results: mean OS was
50.4 months in the two teams prioritizing aggressive
approach, and 40.1 months in the others departments
(p = 0.15).
DISCUSSION
Our results suggest that, in the context of non-resectable,
advanced stage ovarian cancer, standard surgery is just as
beneficial as radical surgery regarding survival outcomes.
Complete cytoreduction is the main objective in the
surgical management of advanced stage ovarian cancer.6
Considering our whole population (N = 527), complete
resection was achieved in most patients (71 %) requiring
upper abdominal procedures in 185 cases. This perfectly
illustrates the paradigm shift toward more extensive
debulking surgeries described by Chi et al. in order to
improve survival outcomes.13 The wider acceptability of
extended surgical procedures has thus contributed to an
increase in the rate of complete cytoreductions.13,14
Despite tremendous progress in the imaging of peri-
toneal carcinomatosis, the visual evaluation at the time of
laparoscopy and surgery provides the most accurate
information regarding the feasibility of disease resection.15
It is not always possible to completely remove bulky dis-
ease; however, two different approaches can be discussed:
(i) minimizing the extent of surgery in the removal of bulky
masses in order to decrease pre- and postoperative mor-
bidity, albeit with the risk of increasing residual disease;
(ii) minimizing the amount of residual disease with radical
procedures despite a higher risk of surgical morbidity. To
date, it is unclear whether radical surgery should be con-
sidered when it would shift GRB disease to GR1.8
Nevertheless, several studies have pointed out the survival
benefit associated with optimal, but visible, cytoreduction
(GR1) in comparison to suboptimal resection (GRB).
Eisenhauer et al. have reported that additional UAS to
achieve complete or GR1 resection led to similar survival
outcomes than patients without the need for UAS, yet with
identical tumor residue.16 In comparison, women who did
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FIG. 2 Comparative outcomes between the standard procedure and radical surgery groups for (a) disease-free survival, and (b) overall survival,
after Peritoneal Cancer Index adjustment (C10)
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not benefit from UAS and only underwent GRB resection
displayed a poorer prognosis. Notwithstanding, the group
with UAS comprised 23 % of complete cytoreductions,
which has probably impacted the gap observed between
survival outcomes. More recently, Barlin et al. observed
similar survival in patients with GR1 resection, regardless
of the use of UAS to complete the desired cytoreduction.17
They did not provide any comparison with GRB patients,
therefore it was not possible to estimate the specific sur-
vival impact yielded by radical surgery.
According to our data, both surgical approaches led to
similar outcomes, although patients who underwent a
standard surgery had greater residual disease (p\ 10-3).
Patients with radical procedures were more likely to
develop a recurrence within the study follow-up. They also
displayed a trend toward decreased DFS compared with the
SP group, with a gap of almost 6 months (16.5 vs.
22.1 months, respectively; p = 0.068). Regarding OS, we
observed an opposite trend (42.7 vs. 40.2 months), with a
less striking gap. Such a discrepancy prompted us to pro-
pose further hypothesis. (i) The apparent gap in DFS is due
to the difference in tumor extent between the two groups of
patients; however, a similar gap was observed in the sub-
group with a higher PCI. (ii) A more extended
cytoreduction might positively impact recurrence sensi-
tivity to second-line treatments. Indeed, OS after relapse
was apparently improved in the RP group, with an absolute
difference of 9 months after PCI adjustment (28.4 vs.
19.5 months), but once again this was not significant.
Defining a cutoff at 20 for PCI, the difference between
interval and relapse became significant—DFS was
25.4 months in the SP group and 13.6 months in the RP
group (p = 0.03); however, both groups had similar OS,
supporting the lack of evidence regarding surgical benefit
provided by radical procedures, in particular in the context
of wide peritoneal spread of cancer.
TABLE 3 Comparative statistics defining a cutoff at 20 for PCI
Total (N = 50) SP group (N = 34) RP group (N = 16) p-Value
Age [mean (SD)] 61 (10.5) 61 (11.4) 60(8.5) 0.60
PCI [mean (SD)] 23 (2.8) 24 (2.7) 23 (3.0) 0.24
DFS [mean (SD)] 21.3 (15.3) 25.4 (17.5) 13.6 (6.7) 0.03*
OS [mean (SD)] 39.0 (18.6) 35.5 (17.9) 37.9 (20.4) 0.52
OS after relapse [mean (SD)] – 15.9 (12.1) 22.8 (18.9) 0.48
FIGO stage 0.15
IIIC 46 (92.0) 30 (88.2) 16 (100)
IV 4 (8.0) 4 (11.8) 0 (0.0)
Neoadjuvant CT 0.04*
Yes 21 (42.0) 11 (32.4)a 10 (62.5)b
No 29 (58.0) 23 (67.6) 6 (37.5)
Histological type 0.79
Serous papillary 34 (68.0) 23 (67.7) 11 (68.7)
Endometrioid 10 (20.0) 8 (23.5) 2 (12.5)
Undifferentiated 2 (4.0) 1 (2.9) 1 (6.3)
Other 4 (8.0) 2 (5.9) 2 (12.5)
Residual disease, mm 0.104
B10 26 (52.0) 15 (44.1) 11 (68.7)
[10 24 (48.0) 19 (55.9) 5 (31.3)
Relapse 0.034*
No 8 (16.0) 8 (23.5)a 0 (0.0)b
Yes 42 (84.0) 26 (76.5) 16 (100)
Condition 0.12
Alive 17 (34.0) 14 (41.2) 3 (18.8)
Dead 33 (66.0) 20 (58.8) 13 (81.2)
Data are expressed as n (%) unless otherwise specified
SP standard procedure, RP radical procedure, SD standard deviation, PCI Peritoneal Cancer Index, DFS disease-free survival, OS overall
survival, FIGO International Federation of Gynecology and Obstetrics, CT chemotherapy
* Statistical significance
a,b There is a statistical significance in the comparison between the groups marked with a different letter
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Contrary to previous reports, we have included both
primary and delayed surgeries. This was justifiable for two
reasons. First, treatment schedule did not impact prognosis
on Cox proportional analysis (HR = 1.15, p = 0.43),
agreeing with conclusions of the recent EORTEC ran-
domized trial.3 Second, making a decision concerning the
surgical approach in a patient where the disease cannot be
completely removed despite the use of neoadjuvant
chemotherapy is difficult, and we aimed to provide some
relevant information that could be applied to routine sur-
gical practice. According to our data, the surgical decision
did not affect patients’ outcome in this specific context.
In our study population, the amount of residual disease
after debulking surgery did not impact survival (HR 1.045;
p = 0.058). Such a finding goes against usual considera-
tions but proving its accuracy is beyond the scope of this
article. We can hypothesize that prognosis, in the context
of non-resectable, advanced stage ovarian cancer, is also
modulated by biological features participating in disease
therapeutic response and kinetics, far beyond surgical
considerations.
Due to the nature of the study, it does suffer limitations.
Its retrospective design exposes the study to potential risks
of selection bias and confounding risk factors. The small-
sized population might have hindered the strength of our
analysis. Data on second-line treatments were not available
and, consequently, are not able to be discussed.
Nevertheless, the study brings additional and practical
information on an unexplored topic. While we and others
support that complete cytoreduction should be performed
whenever possible, there is no consensus in the context of
surgical failure. The great heterogeneity among the seven
centers regarding surgical attitude supports that, in such
cases, proverbs and personal feelings are more customary
than evidence of science. Some will vow by primum non
nocere and reduce the extent of the resection to circumvent
surgery-associated morbidity in order not to delay systemic
treatment. Others will support the more the better, prefer-
ring a more radical approach. Despite increased morbidity,
most patients are able to receive postoperative
chemotherapy after UAS;18 however, delayed initiation of
chemotherapy is associated with poorer outcomes. Wright
et al. have reported that women who began therapy more
than 12 weeks after surgery were 32 % more likely to die
from their tumors.19 In this study, we highlight the fact
that, in the context of non-resectability, surgical manage-
ment is not binary, with an attitude superior to another.
Expected disease sensitivity to first- and second-line
treatment should also participate in the decision through
the screening of individual biological tumor features.
DISCLOSURES Fabien Vidal, Haya Al Thani, Pascale Haddad,
Mathieu Luyckx, Eberhard Stoeckle, Philippe Morice, Eric Leblanc,
Fabrice Lecuru, Emile Daraı¨, Jean-Marc Classe, Christophe Pomel,
Ziyad Mahfoud, Gwenael Ferron, Denis Querleu, and Arash Rafii
have declared no conflicts of interest.
REFERENCES
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA
Cancer J Clin. 2010;60(5):277–300.
2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz
FJ. Survival effect of maximal cytoreductive surgery for
advanced ovarian carcinoma during the platinum era: a meta-
analysis. J Clin Oncol. 2002;20(5):1248–1259.
3. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy
or primary surgery in stage IIIC or IV ovarian cancer. N Engl J
Med. 2010;363(10):943–953.
4. Rauh-Hain JA, Rodriguez N, Growdon WB, et al. Primary
debulking surgery versus neoadjuvant chemotherapy in stage IV
ovarian cancer. Ann Surg Oncol. 2012;19(3):959–965.
5. Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in
patients with FIGO stage IIIC to stage IV ovarian, fallopian, and
peritoneal cancer in day-to-day practice: a Retrospective French
Multicentric Study. Int J Gynecol Cancer. 2012;22(8):1337–
1343.
6. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of
complete cytoreduction to no gross residual disease for advanced-
stage ovarian cancer: A meta-analysis. Gynecol Oncol.
2013;130(3):493–498.
7. Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection
at the time of primary cytoreduction for advanced ovarian cancer.
A multi-center analysis of surgical and oncological outcomes.
Gynecol Oncol. 2012;126(2):220–223.
8. Chang SJ, Bristow RE. Evolution of surgical treatment paradigms
for advanced-stage ovarian cancer: redefining ‘optimal’ residual
disease. Gynecol Oncol. 2012;125(2):483–492.
9. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I,
Pfisterer J. Role of surgical outcome as prognostic factor in
advanced epithelial ovarian cancer: a combined exploratory
analysis of 3 prospectively randomized phase 3 multicenter trials:
by the Arbeitsgemeinschaft Gynaekologische Onkologie Studi-
engruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
d’Investigateurs Nationaux Pour les Etudes des Cancers de
l’Ovaire (GINECO). Cancer. 2009;115(6):1234–1244.
10. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of
diameter of largest residual disease on survival after primary
cytoreductive surgery in patients with suboptimal residual
epithelial ovarian carcinoma. Am J Obstet Gynecol.
1994;170(4):974–979; discussion 979–980.
11. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of
cytoreductive surgery on recurrence-free interval and survival in
small-volume stage III epithelial ovarian cancer: a Gynecologic
Oncology Group study. Gynecol Oncol. 1992;47(2):159–166.
12. Rafii A, Stoeckle E, Jean-Laurent M, et al. Multi-center evalua-
tion of post-operative morbidity and mortality after optimal
cytoreductive surgery for advanced ovarian cancer. PloS One.
2012;7(7):e39415.
13. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progres-
sion-free and overall survival in advanced ovarian cancer as a
result of a change in surgical paradigm. Gynecol Oncol.
2009;114(1):26–31.
14. Harter P, Muallem ZM, Buhrmann C, et al. Impact of a structured
quality management program on surgical outcome in primary
advanced ovarian cancer. Gynecol Oncol. 2011;121(3):615–619.
15. Le Brun JF, Ferron G, Vaysse C, et al. Laparoscopic observation
of the diaphragm undersurface in the staging of peritoneal
F. Vidal et al.
carcinomatosis: comparison of three optical systems. Eur J
Obstet Gynecol Reprod Biol. 2012;164(1):65–68.
16. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of
extensive upper abdominal surgery to achieve optimal cytoreduc-
tion improves survival in patients with stages IIIC-IV epithelial
ovarian cancer. Gynecol Oncology. 2006;103(3):1083–1090.
17. Barlin JN, Long KC, Tanner EJ, et al. Optimal (B1 cm) but
visible residual disease: is extensive debulking warranted?
Gynecol Oncol. 2013;130(2):284–288.
18. Chi DS, Zivanovic O, Levinson KL, et al. The incidence of major
complications after the performance of extensive upper abdomi-
nal surgical procedures during primary cytoreduction of advanced
ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol.
2010;119(1):38–42.
19. Wright JD, Herzog TJ, Neugut AI, et al. Effect of radical
cytoreductive surgery on omission and delay of chemotherapy for
advanced-stage ovarian cancer. Obstet Gynecol. 2012;120(4):
871–881.
Incomplete Cytoreduction in Ovarian Cancer
